Products

A cell-permeable, reversible, and ATP-competitive Ca²⁺ antagonist with anti-vasospastic properties. Inhibits protein

kinase A (K_i = 1.6 µM), protein kinase G (K_i = 1.6 µM), and myosin light chain kinase (K_i = 3.6 µM). Also reported to

potently inhibit Rho-associated kinase (ROCK; IC₅₀ = 10.7 µM). Prevents apoptosis and enhances the survival and

cloning efficiency of dissociated hES cells without affecting their pluripotency.

A cell-permeable, selective, reversible, and ATP-competitive inhibitor of Rho kinase activity (IC₅₀ = 25 µM). Does not 

inhibit the activation of Rho kinase nor does it affect the in vitro activities of MLCK, PKCα, and SAPK2a/p38α. Shown to

be 5-fold less potent than Y-27632 (Cat# CD0141; IC₅₀ ~5 µM), and display a similar specificity profile as H-89 (Cat. No.

371963). Affects cell migration, inhibits blebbing (IC₅₀ ~12 µM in M2 cells), and decreases stress fibers in Bulb

3T3 cells at 50 µM.

A highly potent, cell-permeable, reversible, and selective inhibitor of Rho-associated protein kinase (Ki = 140 nM for

p160^ROCK (ROCK-I). Also inhibits ROCK-II with almost equal potency. Inhibition is achieved by competing with ATP for

binding to the catalytic site. Exhibits 10- to 50-fold lower affinity for PKC_ε than p160^ROCK. Does not affect the activity of

p21-activated protein kinase (PAK) even at high concentrations (~100 µM). Also acts as a potent inhibitor of agonist-

induced Ca²⁺ sensitization of myosin phosphorylation and smooth muscle contractions (IC₅₀ = 700 nM for

phenylephrine-induced contractions in aortic strips). Prevents apoptosis and enhances the survival and cloning

efficiency of dissociated hES cells without affecting their pluripotency.

Catalog No.

Product Name

Size

CD0160

Fasudil (HA 1077) Dihydrochloride – ROCK Inhibitor

250mg, 500mg, 1g,

2g & 5g

CD0222

Rho Kinase Inhibitor III (Rockout) – ROCK Inhibitor

5mg, 10mg, 50mg,

100mg & 200mg

CD0141

Y-27632 – ROCK Inhibitor

1mg, 5mg, 10mg, 25mg,

50mg ,100mg, 250mg & 1g